We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Angle Plc | LSE:AGL | London | Ordinary Share | GB0034330679 | ORD 10P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.50 | 5.00% | 10.50 | 2,682,988 | 09:51:45 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 10.00 | 11.00 | 11.00 | 10.00 | 10.00 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Business Services, Nec | 2.19M | -20.13M | -0.0624 | -1.76 | 32.26M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 10:30:25 | O | 12,500 | 10.22 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 23/5/2025 | 07:00 | UK RNS | Angle PLC Notice of Results |
| 28/4/2025 | 07:00 | UK RNS | Angle PLC RESULTS SUPPORTING ANGLE’S HER2 ASSAY PROGRAMME |
| 21/3/2025 | 14:25 | ALNC |  Angle hails successful completion of Eisai contract; approval by Astra |
| 21/3/2025 | 07:00 | UK RNS | Angle PLC Issue of LTIP Options and Share Options |
| 21/3/2025 | 07:00 | UK RNS | Angle PLC Results of Eisai Phase 2 pilot study |
| 06/2/2025 | 07:00 | UK RNS | Angle PLC Novel findings using Parsortix |
| 29/1/2025 | 16:26 | ALNC | Angle reports breakthrough in dual cancer DNA analysis |
| 29/1/2025 | 07:00 | UK RNS | Angle PLC Analysis of CTC-DNA and ctDNA using Illumina assay |
| 24/1/2025 | 10:05 | UK RNS | Angle PLC Parsortix used in research paper from ETH Zurich |
| 23/1/2025 | 14:22 | ALNC | Angle fails to win market confidence despite narrowing loss in 2024 |
Angle (AGL) Share Charts1 Year Angle Chart |
|
1 Month Angle Chart |
Intraday Angle Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 23/5/2025 | 10:21 | ANGLE PLC - 2019 THREAD - LIQUID BIOPSY COMPANY | 28,923 |
| 15/4/2025 | 15:05 | SHAREHOLDERS ACTION GROUP | 585 |
| 26/3/2025 | 23:48 | AGL has been Jinxed by the God of Shite. 10p Target | 285 |
| 18/2/2025 | 11:56 | ANGLE 2016 – LIQUID BIOPSY TAKEOVER TARGET | 11,464 |
| 12/2/2025 | 20:41 | 6 monthly AGL check in | 4 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 09:30:26 | 10.22 | 12,500 | 1,277.50 | O |
| 09:26:33 | 10.44 | 1 | 0.10 | O |
| 09:25:59 | 10.03 | 100,000 | 10,026.60 | O |
| 09:24:29 | 10.15 | 50,000 | 5,075.00 | O |
| 09:23:45 | 10.24 | 100,000 | 10,236.00 | O |
| Top Posts |
|---|
Posted at 20/5/2025 15:25 by 5oletrader For anyone who wants to try a different lens - instead of repeatedly reading posts of the same old ilk.- Both the developed assays (AR and DDR) have been approved for use by AstraZeneca and we are currently using the assays to test blood samples from patients. These developments put ANGLE in the position to be able to execute large scale clinical trials for AstraZeneca." https://www.londonst Supplier agreement to develop DDR assay - 150k - JOB DONE https://www.londonst Supplier agreement to develop AR detection assay - 550k - JOB DONE https://www.londonst So CURRENT STATUS: We are using the assays to test blood samples from patients." QUESTION? (not one person switched onto this): - If AZN is ALREADY using these assays on patient samples, do you think AGL are doing that for free? You could always 'ask' the company? - Maybe AZN are paying AGL on a per sample basis right now? NOT under a full clinical trial CONTRACT (yet), but under a real-world feasibility and operational validation phase. Why? Because the R&D is JOB DONE and now the focus shifts to pre-deployment QA. - AGL - is NOW on the BRIDGE: At pre-deployment QA phase - the final step between development success and LARGE-SCALE integration! - So while 'some' spread FUD about Parsortix being useless and AZN losing interest - ask yourself - is it? and are they? What we KNOW: - The assays (AR and DDR) are validated, in use, and described by AGL as "APPROVED FOR USE BY AZN". The story is now about operational readiness. How long? This QA phase typically spans 6-12 months in similar diagnostics rollouts. While AGL hasn't confirmed timelines (how far along this time frame are AGL?), a plausible to-do list include: - Testing hundreds of real patient samples under clinical trial-like conditions - Stress-testing logistics (turnaround, reproducibility, sample integrity across locations) - Aligning with ILMN's downstream workflows (multiomic compatibility, data handling, cost-per-sample) - Standardising SOPs across internal teams and external trial sites Also, - How many patient samples will AZN want to stress test? 100? - How many cancer TYPES will AZN want to run 100 samples on? Lung, Breast, Ovarian, Blood, Prostate, Liver, Pancreatic? 700 samples? Possible? https://www.astrazen What will AGL be charging on a per sample basis? 2k+? - The point = SHORT TERM REVENUE GENERATION. Hence the cash runway to 2026. This also ties in directly with AGL's latest trading update: - We expect revenues in 2025 to be higher than 2024, with the potential for a major Phase 3 clinical trial." https://www.londonst Also Why mention Phase 3? Companies don't reference Phase 3 lightly in financial updates - to me it signals live dialogue with partners and internal planning aligned to real clinical deployment. You don't just say "potential for Phase 3"! That ONLY happens if pre-deployment QA is progressing well. - TRIPARTITE" - KNIGHTS of the ROUND TABLE: In my opinion this isn't three companies acting independently. It's a QUIETLY coordinated triad - AZN, ILMN, and AGL - shaping the future of oncology diagnostics on their terms. - AZN brings the drugs, the trials, and the regulatory clout. - ILMN brings the omics platforms, data engines, and healthcare penetration. - AGL brings the patient-side sampling tech that makes real-world blood-based stratification viable and scalable. I'd argue they are engineering the clinical diagnostics pipeline from front-end capture to treatment outcome - and because they control every layer of that stack, they also control what gets disclosed, when, and how! - No flashy press releases. No early declarations. Why? Because real competitive advantage comes from: - Building the pipeline quietly - Validating it internally - Locking in exclusivity and standards - And launching with scale and authority, not drip feeding headlines Are they focused on building a globally dominant diagnostic machine? - Is the narrative being held back on purpose? Because when it's finally revealed, it will already be fully integrated, clinically validated, and commercially aligned. - Its positioning 101! https://youtu.be/iao - AZN + ILMN - TELL ME WHAT YOU WANT, WHAT YOU REALLY REALLY WANT: Let's not overcomplicate this - both want FULL control of the cancer patient journey, from first blood draw to treatment decision, powered by real-time molecular data. And they're racing to scale it globally: - ASTRAZENECA: Their goal is precision patient stratification at scale - across trials and clinical settings. In clinical TRIALS, that means: - Enrolling only the right patients (AR, DDR, HER2 etc) - Faster recruitment, faster readouts, faster approvals - Biomarker-defined subgroups to maximize drug efficacy and hit endpoints In clinical PRACTICE, that means: - Ensuring the right patient gets the right drug - Real-time companion diagnostics to support drug prescriptions (e.g. EnHertu for HER2-low) - Avoiding resistance and failure by monitoring evolving biomarkers via repeat blood tests AZN want a standardised front end that plugs into global trial networks and oncology clinics. - ILLUMINA: Their goal is owning the data funnel - from blood tube to omics analysis. In clinical TRIALS, this means: - Every patient = multiomic dataset (DNA, RNA, epigenetics, proteomics) - Fed into Illumina systems for sequencing, AI analysis, and reporting - Positioned as the gold standard for pharma biomarker discovery In clinical PRACTICE, this means: - Plugged into national health systems and hospitals - Recurring revenue from sequencing, reagents, and downstream informatics - Monetising insights via partnerships, data licensing, and personalised medicine platforms ILMN want clean, structured input for their machines and software. - ANGLE: Angle solves the front-end problem for both AZN and ILMN: - Captures viable CTCs, not just cell-free debris - Enables dual analysis from the same blood draw - Standardised, IP-protected process with regulatory momentum - Scalable, automatable, and accredited lab compliant This is the infrastructure that makes the story possible. And; IF" AZN and ILMN want FULL control from bench to bedside - they either: - Buy ANGLE, or - Lock it in permanently with exclusive rights https://www.londonst - The webinar is the first JOINT MARKETING initiative for ANGLE and ILLUMINA. Because it harvests intact cancer cells (rather than DNA fragments of dead cells), ANGLE's Parsortix system offers the potential to undertake multiomics by enabling RNA and protein sequencing on Illumina platforms which is "NOT POSSIBLE" with ctDNA. https://youtu.be/jtE - Either way, this ends on ANGLE's terms - not the bulletin boards. - CASH FUD - QUESTION?: - If AZN is already using the tech, already paying for samples, and already planning Phase 3 - are we closer to dilution or collaboration??? Cash is NOT the current issue - it's a 2026 issue unless you ignore the facts already in play. ATB |
Posted at 16/5/2025 09:27 by washingmachine YasXI’m well aware AGL have to pull a rabbit out of the bag before results, Which from to day leaves about 2 weeks. This is the bet , if they do Odviously the share price if beneficially monetary will rise. Going in to results without will not just be worrying but I’m prepared for the hit. My average is under 8 pence fortunately for me.. so a approx 3 point hit I’ve factored in Newland always in the past has released a flurry of news before AGL at present is NOT for widows and orphans ! |
Posted at 22/4/2025 09:13 by bones698 Agree the share options is no indication as years have gone past with high options but the share price continues to fall . The rumblings on deals and press around illumia and bioview is more interesting but needs official news and revenues attached to any such deal to drive the share price .they are leaving it late but the aacr might just be what they need |
Posted at 11/4/2025 10:58 by ohwhatfun Reality on numbers for a raise.Share price 7.75p market cap £25m rough numbers 325m shares in issue. Those thinking can’t do than 10p. Nice 10p £10m raise for ease 100m shares. Which would mean 425m shares at a 10p price equates to the market cap jumping from £25m to £42.5m in an awful market in a constant failed promise company. It doesn’t work like that. Just to stay at a £25m market cap the raise for £10m would need to be around 4.5p. That’s the reality of dilution which is why share prices get trashed down pre raise then discounted. |
Posted at 09/4/2025 18:01 by ohwhatfun YasAs you probably well know, if a broker can’t drum up enough interest from their inner circle of clients, they have to seek others, which results in fire sale discount to get the money but also fund raise smoke visible well beyond any NDA barrier. In the worst case scenario the bucket shop game where all and sundry get to hear, followed by posts on sites saying raise coming, just after they go short. That forces the company to admit they are in the process of raising funds. The share price dives as punters exit, which serves those involved in the raise to push the strike price lower and lower, with often an agreed price then dropping further last minute (typical dirty trick). Share price falls and then discount from there, so it could he carnage here. Did Angle not say that last year it’s a tough market, some parties would not even entertain the NDA process to even look who was after funding. I was thinking 15p last time 8 ish p this time and a 12p average not really that bad, but you are right, a big fat rabbit out of the hat is needed and quick but even then a raise price could still be low. |
Posted at 24/3/2025 16:47 by bones698 ST if they think the shares are so undervalued why don't they buy them with their own money now at a price less than they would end up paying for the options (10p). Most directors who see an opportunity would buy the shares in the open market . The share price has been suppressed for some time now but no director buys .we know AN has plenty of money ,he told shareholders that not so long ago but doesn't buy shares when the share price is low . They have not been in a closed period for the last 18 months .I agree with the rest it was decent news just lacking an actual deal but I find the. Ltip stuff a bridge too far . |
Posted at 24/3/2025 09:16 by 5oletrader My turn.-EISAI:Reading the RNS I note AGLs comment:... "significant differences in HER2 CTC status and numbers of CTCs and CTC "clusters" were observed between the results for two different timepoints for the same patient BEFORE and AFTER treatment" ...What remains unsaid here: AGL highlighted a "major" clinical insight - HER2 status is "not" stable, and CTC analysis is the "only way" to track it in REAL-TIME. EISAI "may" have seen data that made them rethink BB-1701's feasibility, but still value PARSORTIX for other projects. This was "not" a failure for AGL - the findings "could" be VERY VALUABLE to "other" ADC developers, including BlissBio.So... This HER2 fluctuation insight "could" redefine "how" PHARMA approaches patient selection for HER2-ADCs. If AGL can CAPITALISE on this, it could be a long-term "WIN" despite EISAI abandoning and walking away from BB-1701.In essence, EISAI may of just saved themselves "HUNDREDS of MILLIONS" on a doomed Phase 3 trial by cutting their losses early. If AGL helped the "FAIL FASTER" narrative - this would be a "positive" validation for PARSORTIX - even if the market doesn't see it that way (yet).-ASTRAZENECA:R |
Posted at 22/3/2025 10:10 by seball Read the RNS. These are options. IF they get the share price through the qualifying share price, THEN they pay 19p per share.If they get the share price to 50p, they can have as many 10p shares as they want, as far as I am concerned. If you cant read and understand a simple RNS, why invest? |
Posted at 21/3/2025 21:04 by millwallfan Just a thought. Share price 9p. Circa 322 million shares in issue. I’m guessing vast majority of shareholders well under water ( 31.6p average for me). If there was a lowball bid at + 33% = 12p and it was accepted I would have no choice in a loss of almost 20p per share. IF I still believe the company has a viable future in say 12 months I think I would actually be prepared to accept a rights only issue at 2p per share which would raise about £6 million plus of working capital. Yes my average would increase to 33.6p per share - but at least I would still have skin in the game and the chance of a decent return in future years - even if it was just my total investment back !!! To raise £6 m in an open offer at a discounted 6p per share we would need buyers for an extra 100 million shares = a 31% dilution in my shares - and that’s then dependent on achieving full take up by lots of new investors which IMHO is highly unlikely given past performance since FDA !!! I don’t think I would buy one third more shares than my current holding at 6p just to maintain my current % level of holding if the post raise share price was likely to have dropped to say 7p. I’m sure there’s lots of flaws in my thinking 😂 |
Posted at 21/3/2025 08:43 by seball Read the RNS. These are options. IF they get the share price through the qualifying share price, THEN they pay 19p per share.If they get the share price to 50p, they can have as many 10p shares as they want, as far as I am concerned. If you can’t read and understand a simple RNS, why invest? |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
.png){kind=logo}
